ストックスクリーナーアプリを入手
5.225
1.26%
0.065
アフターアワーズ：
5.27
0.045
+0.86%
前日終値:
$5.16
開ける：
$5.2
24時間の取引高:
10,955
Relative Volume:
0.15
時価総額：
$16.76M
収益：
-
当期純損益:
$-45.52M
株価収益率:
-0.5372
EPS:
-9.7265
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
+0.10%
1か月 パフォーマンス:
-14.76%
6か月 パフォーマンス:
-32.45%
1年 パフォーマンス:
+1,398%
1日の値動き範囲:
$5.14
$5.335
1週間の範囲:
$4.98
$5.35
52週間の値動き範囲:
$0.3195
$20.00
Passage Bio Inc Stock (PASG) Company Profile
名前
Passage Bio Inc
セクター
電話
(267) 866-0312
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
5.225 | 16.55M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-04-21 | ダウングレード | Wedbush | Outperform → Neutral |
| 2026-03-31 | 開始されました | Oppenheimer | Outperform |
| 2026-02-10 | 再開されました | Chardan Capital Markets | Buy |
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-09-03 | 開始されました | Rodman & Renshaw | Buy |
| 2022-03-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-19 | ダウングレード | Goldman | Buy → Neutral |
| 2021-07-01 | 開始されました | Raymond James | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-03-04 | アップグレード | Goldman | Neutral → Buy |
| 2021-02-04 | 開始されました | Guggenheim | Buy |
| 2021-01-25 | 開始されました | Wedbush | Outperform |
| 2021-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 開始されました | Citigroup | Neutral |
| 2020-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-25 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2020-03-24 | 開始されました | Cowen | Outperform |
| 2020-03-24 | 開始されました | Goldman | Buy |
| 2020-03-24 | 開始されました | JP Morgan | Overweight |
すべてを表示
Passage Bio Inc (PASG) 最新ニュース
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentMarket Buzz Alerts - Newser
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Operational ProgressCrowd Sentiment Entry - Newser
Passage Bio Inc. (PASG) Holds Steady Near Support as Biotechnology Sector Faces HeadwindsBeta Neutral Pair - Newser
Director Sondhi Dolan receives 10,539 Passage BIO (PASG) stock options - Stock Titan
Passage BIO (NASDAQ: PASG) director Derrell Porter receives grant of 10,539 stock options - Stock Titan
Passage BIO, Inc. (PASG) director gets 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director Sandip Kapadia awarded 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director receives 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) awards 10,539 options to director at $5.08 - Stock Titan
Passage Bio Inc stock (US70267E1055): gene therapy developer back in focus after recent moves - AD HOC NEWS
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Passage Bio Inc stock (US70267E1055): gene therapy hopes meet analyst caution - AD HOC NEWS
Passage Bio stock (US70267E1055): Cuts 75% of workforce after FDA feedback - AD HOC NEWS
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
TradingKey - TradingKey
Krabbe Disease Treatment Market to Reach USD 786.45 Million - openPR.com
TD Cowen Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
MSN Money - MSN
GM1 Gangliosidosis Treatment Market to Reach USD 626.86 Million - openPR.com
Passage BIO, Inc. 1Q 2026: Net loss $(7.6)M, EPS $(2.36) — 10-Q Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Passage Bio (NASDAQ: PASG) faces cash shortfall, cuts workforce 75% - Stock Titan
CCORF Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Why Passage Bio (PASG) business model holds up in any market (Smart Money Active) 2026-05-11Social Flow Trades - newser.com
A Quick Look at Today's Ratings for Passage Bio(PASG.US), With a Forecast Between $21 to $32 - Moomoo
Number of shareholders of Passage Bio, Inc. – BOATS:PASG - TradingView
A Quick Look at Today's Ratings for Passage Bio(PASG.US), With a Forecast Between $8 to $23 - Moomoo
Passage Bio Inc expected to post a loss of $2.79 a shareEarnings Preview - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Layoff Tracker: Passage axes 75% of staff, explores strategic alternatives - BioSpace
Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
PASG (Passage Bio) reports wider-than-expected Q4 2025 loss, shares dip 1.02% amid negative investor sentiment.Retail Trader Ideas - Newser
Canaccord Genuity Remains a Buy on Passage Bio (PASG) - The Globe and Mail
PASG Maintains Rating by Oppenheimer -- Price Target Lowered to $15 - GuruFocus
PASG Downgraded by Chardan Capital -- Price Target Lowered to $7 - GuruFocus
Passage Bio (PASG) Downgraded by Wedbush Analyst - GuruFocus
PASG Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - marketscreener.com
PASG Downgraded by Wedbush -- Price Target Lowered to $8.00 - GuruFocus
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - marketscreener.com
Passage Bio downgraded to Neutral from Buy at Chardan - TipRanks
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday - Benzinga
Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news - Investing.com South Africa
Oppenheimer Adjusts Price Target on Passage Bio to $15 From $30, Maintains Outperform Rating - marketscreener.com
Wedbush Downgrades Passage Bio to Neutral From Outperform, Cuts Price Target to $8 From $32 - marketscreener.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback By Investing.com - Investing.com Australia
Passage Bio Inc (PASG) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):